The exclusive research report on the Global Genotyping Market 2020 examines the market in detail along with focusing on significant market dynamics for the key players operating in the market.
Global Genotyping Market Research Report 2023 – To provide detail analysis of the market structure along with estimated future growth forecast for the next 6 years about various segments and sub-segments of the Global Genotyping Market. Experts analyze the Global Genotyping Market based on various factors – price analysis, supply chain analysis, Porters Five Force Analysis etc.
The Global Genotyping Market is projected to have a healthy growth at an exponential 22.5% CAGR during the forecast period (2018-2023). Genotyping helps users in understanding a living organism’s genetic structure such as humans, animals, plants and microorganisms. It is basically an organism’s genetic mapping that includes both DNA sequencing as well as sequenced DNA’s analysis. Genotyping has various uses in medicine, agriculture and basic scientific research.
Also Read : https://www.medgadget.com/2019/06/genotyping-market-to-register-at-22-5-cagr-till-2023-with-global-players-as-beckman-coulter-inc-fluidigm-corporation-f-hoffmann-la-roche-ltd-general-electric-company-etc.html
There are several factors that are driving the growth of the genotyping market. These factors according to the MRFR report include advancements in technology, rising prevalence of target diseases namely Alzheimer’s, diabetes and cancer, introduction of new technologies which reduce errors and offer effective results, increasing R&D activities in healthcare, rise in genetic ailments, surge in need for personalized medication and decrease in genotyping service price. On the contrary, factors such as dearth of skilled professionals and unfavorable reimbursement policies may hamper the growth of the genotyping market.Key Players
Market Research Future (MRFR) recognizes the following companies as the key players in Genotyping Market: There are plenty of large and small market players which operate in this market all over the globe.
The key players in the global genotyping market include Affymetrix Inc. (USA), Agilent Technologies Inc. (USA), Beckman Coulter Inc. (USA), Fluidigm Corporation (USA), F. Hoffmann-La Roche Ltd. (Switzerland), General Electric Company (USA), Illumina Inc. (USA), Qiagen (Germany), Sequenom (USA), and Thermo Fisher Scientific Inc. (USA).
Latest Industry News
- NRGene and Macrogen Corp are set to launch a joint sequencing-based genotyping service, ArrayMAGIC. 12 JAN 2019
- In Cordova, robots and robotic body parts implanted into disabled humans are helping the scientific procedures. Robots have helped a genetic testing lab complete 20 millionth sample. 25 JAN 2019
Market Research Future report offers an all-inclusive segmental analysis of the genotyping market on the basis of product, end-user, application and technology.
Based on product, it is segmented into services, reagents and kits and instruments. Of these, reagents and kits will have the largest share in the market.
Based on end-user, the genotyping market is segmented into R&D centers, hospitals, diagnostic centers and academic institutes.
Based on application, it is segmented into personalized medicine, drug discovery and development, agriculture diagnostics and academic research. Of these, personalized medicine will lead the market and is expected to have the fastest growth.
Based on technology, the genotyping market is segmented into polymerase chain reaction (PCR), sequencing, microarray, mass spectrometry and capillary electrophoresis. Capillary electrophoresis is further segmented into single-strand conformation polymorphism (SSCP), restriction fragment length polymorphism (RFLP) and amplified fragment length polymorphism (AFLP). Microarrays is further segmented into peptide microarrays, MMChips, DNA microarrays and antibody microarrays. Sequencing is further segmented into sanger sequencing, pyrosequencing and next-generation sequencing. Of these, sequencing will lead the market during the forecast period.
The regional segmentation of the global genotyping market has segmented the global market into regional markets known as The Americas (North America & South America), Europe, Asia Pacific, and the Middle East & Africa (MEA). The Americas hold the largest market share of the global market as North America alone is capable of holding this share anyways. Due to technology, North America is a bigger market than South America. In North America, the market is growing due government support for R&D, increasing cases of genetic disorders, the availability of advanced medical facilities, and the presence of many key market players. In North America, the vital country-specific markets are USA and Canada. In South America, Argentina and Brazil are two strong economies that can be suitable markets in the future.
Europe is a major regional market due to the well-established healthcare sector. In this region, the market is growing due to various governments funding the R&D, presence of many key market players, rising investment into R&D by pharmaceutical companies, and the availability of advanced medical facilities that are second only to North America. In Europe, due to reasons same as The Americas, Western Europe is a bigger market than Eastern Europe. The country-specific markets France, Germany, Italy, Spain, and the UK, followed by the remaining countries of Western Europe as well as Eastern Europe.
During the forecast period, the Asia Pacific region has been anticipated to rise as the fastest-growing regional market. In the Asia Pacific region, the market is growing due to increasing disposable income, rising investment by market players in this region, the presence of stable healthcare sector that is growing gradually, and lastly, supportive government policies. The key country-specific markets in this region are Australia, China, India, Japan, and South Korea, followed by the remaining countries of the Asia Pacific region.
The MEA region is the smallest regional market. In this region, the market is small and limited due to poor countries, lack of awareness, lack of advanced medical facilities, low standard of medical facilities, lack of education, lack of healthcare facilities, and most governments not considering healthcare a priority.
FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/genotyping-market-6635